GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Astonea Labs Ltd

Astonea Labs Q2 FY27 Consolidated Revenue up 44.6% YoY to ₹95.86 Cr

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 14 Nov 2026, 05:55 PM IST  ·  BSE ID: 54f7c7f7-01a4-4d65-b418-b7251b238854
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest half-year financial results, showing significant growth in sales and profits, and plans to acquire a new subsidiary.
🤖 AI Summary
  • Astonea Labs reported Unaudited Consolidated Revenue from operations of ₹95.86 crore for H1 FY27, up 44.6% YoY.
  • Consolidated Profit After Tax (PAT) for H1 FY27 reached ₹4.82 crore, an increase of 153.3% YoY.
  • The Board approved related party transactions with Longevity Science Private Limited for up to ₹12,00,00,000/-.
  • Astonea Labs plans to subscribe to 51% of Longevity Science Private Limited's share capital, making it a subsidiary.
  • The company voluntarily adopted Indian Accounting Standards (Ind AS) effective April 01, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from operations (H1 FY27)
₹95.86 crore
+44.6%
Profit after tax (H1 FY27)
₹4.82 crore
+153.3%
EBITDA (H1 FY27)
₹13.20 crore
+140.7%
Gross borrowings (30 Sep 2026)
₹57.15 crore
Debt to equity (30 Sep 2026)
0.79x
🏢 How This Affects the Company
📈
Business Impact
Revenue from operations grew by 44.6% YoY, driven by a larger share of sales from own OTC brands, and new distributors were appointed in Central and South America for export growth.
💰
Financial Impact
Consolidated PAT increased by 153.3% YoY, with PAT margin rising by 216 bps to 5.0%. Gross borrowings increased to ₹57.15 crore, raising the debt to equity ratio to 0.79x.
⚙️
Operational Impact
Tablet output capacity increased by 35%, and the plant is compliant with revised Schedule M and WHO-GMP. However, regulatory audits and a plant fire caused temporary slowdowns and an exceptional loss of ₹0.46 crore.
⚠️
Risk Impact
The exceptional loss of ₹0.46 crore from a plant fire highlights operational risk. The increase in gross borrowings and debt to equity ratio from 0.64x to 0.79x indicates increased financial leverage.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders are indirectly affected by the company's financial performance and strategic decisions to expand through a new subsidiary, Longevity Science Private Limited, and proposed related party transactions up to ₹12,00,00,000/-.
🔍
Management Signal
Management signals an intent for continued growth through increased capacity, expansion of OTC brands, export market penetration, and strategic subsidiary acquisitions, while aiming to maintain debt within specified limits.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — verify if revenue growth and margins are sustained.
Update on Longevity Science Private Limited — confirm subsidiary completion and impact.
Export market progress — monitor product registrations in Ethiopia and Kenya.
MEDIUM RISK Increasing debt, a recent plant fire, and the integration of a new subsidiary present operational and financial risks.
💡 Investor Takeaway
Astonea Labs reported H1 FY27 consolidated revenue of ₹95.86 crore, a 44.6% YoY increase. Net profit rose 153.3% YoY to ₹4.82 crore. The company targets ₹215 crore revenue for FY27, with H2 FY27 revenue needing to be about ₹119 crore, up 47% YoY.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from operations increased by 44.6% YoY to ₹95.86 crore in H1 FY27, demonstrating strong top-line growth.
  • Profit after tax grew by 153.3% YoY to ₹4.82 crore in H1 FY27, with PAT margin expanding by 216 bps to 5.0%.

⚠️ Concerns

  • Gross borrowings increased to ₹57.15 crore at 30 September 2026, up from ₹43.00 crore at 31 March 2026, increasing debt to equity to 0.79x from 0.64x.
  • A plant fire on April 27, 2026, resulted in an exceptional loss of ₹0.46 crore, affecting profitability in H1 FY27.
📅 Company Track Record
Astonea Labs has previously reported audited consolidated financial results for FY26, including a new subsidiary incorporation. This filing marks their first half-year results under Ind AS, with H1 FY26 restated. The company's recent past filings indicate ongoing board activity concerning financial results and corporate structure.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What were Astonea Labs' consolidated revenue and profit for H1 FY27?
Astonea Labs reported consolidated revenue from operations of ₹95.86 crore for H1 FY27, with Profit After Tax (PAT) at ₹4.82 crore.
How much did Astonea Labs' revenue and PAT grow year-over-year in H1 FY27?
Revenue from operations grew by 44.6% YoY to ₹95.86 crore, and Profit After Tax increased by 153.3% YoY to ₹4.82 crore in H1 FY27.
What is the status of Astonea Labs' proposed related party transactions?
The Board approved proposed related party transactions with Longevity Science Private Limited for an aggregate value not exceeding ₹12,00,00,000/- during FY27.
What is Astonea Labs' target revenue and margins for FY27?
For FY27, Astonea Labs targets revenue of ₹215 crore or more, an EBITDA margin of 13–15%, and a PAT margin of 5–6%.
What was Astonea Labs' debt to equity ratio at 30 September 2026?
At 30 September 2026, Astonea Labs had gross borrowings of ₹57.15 crore and net worth of ₹72.19 crore, resulting in a debt to equity ratio of 0.79x.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel